Evidence of decreased plasma substance P levels in human essential hypertension and influence of prazosin treatment.
Patients with essential hypertension (n = 45) had significantly lower substance P plasma levels (13.6 +/- 2.30 pg/ml) in comparison with a group of 24 normotensive subjects (45.4 +/- 7.18 pg/ml) analyzed by radioimmunoassay. Prazosin treatment for 2 weeks with 4.5 mg/day enhanced the substance P plasma level depending on its antihypertensive effect. Norepinephrine concentration in plasma was also elevated by prazosin. Dipeptidylpeptidase IV, dopamine-beta-hydroxylase and plasma renin activity were not changed significantly. The results indicate the participation of substance P in pathophysiological processes of human essential hypertension.
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D004152:Dipeptidyl-Peptidases and Tripeptidyl-Peptidases / Q000378:metabolism; D004299:Dopamine beta-Hydroxylase / Q000378:metabolism; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy; D008297:Male; D009638:Norepinephrine / Q000097:blood; D011224:Prazosin / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D012083:Renin / Q000097:blood; D013373:Substance P / Q000097:blood*
D011799:Quinazolines; D013373:Substance P; D004299:Dopamine beta-Hydroxylase; D004152:Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; D012083:Renin; D009638:Norepinephrine; D011224:Prazosin